title: Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells.
abstract: We established long-term cell lines of cytotoxic T lymphocytes (CTL) specific for human T cell leukemia virus type I (HTLV-I) from peripheral blood lymphocytes (PBL) of a patient with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), an HTLV-I-carrier with Sjögren syndrome, and an asymptomatic HTLV-I-carrier, by repeated stimulation with autologous HTLV-I-infected T cells in vitro. CTL derived from the patient with HAM/TSP expressed CD8 antigen, and their function was restricted by HLA-A2. They showed cytotoxic effects predominantly against the target cells expressing HTLV-I p40tax among the autologous B cell lines infected with vaccinia recombinants containing various HTLV-I genes which served as targets. These data are consistent with the previously reported findings that fresh PBL of HAM/TSP patients contain p40tax-specific CTL activity. Furthermore, CTL derived from the patient with Sjögren syndrome without neurological involvement also demonstrated cytotoxicity predominantly to p40tax. The cytotoxicity to the target cells experimentally expressing p40tax was blocked by unlabeled HTLV-I-infected cells possessing HLA-A2. HTLV-I-specific cytotoxicity was also inhibited by unlabeled B cells bearing p40tax. Thus, HTLV-I p40tax-specific cytotoxicity is mediated by the major CTL population activated by native HTLV-I antigens in patients with HAM/TSP or Sjögren syndrome. In contrast to the CTL of these patients, CTL similarly induced from the asymptomatic HTLV-I-carrier, which were highly cytotoxic to autologous HTLV-I-infected T cells, did not show significant levels of cytotoxicity to autologous B cells expressing p40tax.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Biodefence and Medical Virology, Kumamoto University Medical School, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kannagi
authors.forename: S
authors.initials: S
authors.lastname: Harada
authors.forename: I
authors.initials: I
authors.lastname: Maruyama
authors.forename: H
authors.initials: H
authors.lastname: Inoko
authors.forename: H
authors.initials: H
authors.lastname: Igarashi
authors.forename: G
authors.initials: G
authors.lastname: Kuwashima
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Morita
authors.forename: M
authors.initials: M
authors.lastname: Kidokoro
authors.forename: M
authors.initials: M
authors.lastname: Sugimoto
mesh_terms: D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology; D016827:CD8 Antigens / Q000032:analysis*; D002460:Cell Line; D005260:Female; D016356:Gene Products, tax / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology; D015490:HTLV-I Infections / Q000276:immunology*; D006801:Humans; D015493:Paraparesis, Tropical Spastic / Q000276:immunology*; D010641:Phenotype; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D016827:CD8 Antigens; D016356:Gene Products, tax; D015789:HLA-A2 Antigen